Contribution of endothelin receptors and cyclooxygenase-derivatives to the altered response of the rabbit renal artery to endothelin-1 in diabetes

European Journal of Pharmacology

Volumn 534, Issue 1-3, 2006, Pages 178-186

  Marrachelli, Vannina G ^a   Miranda, Francisco J ^a   Alabadí, José A ^a   Lloréns, Silvia ^c   Alborch, Enrique ^a,b  

^a UNIVERSITY OF VALENCIA   (Spain)

^b HOSPITAL UNIVERSITARIO LA FE   (Spain)

^c UNIVERSITY OF CASTILLA LA MANCHA   (Spain)

Author keywords

Arachidonic acid derivatives; Cyclooxygenase; Diabetes; Endothelin ETA and ETB receptors; Endothelin 1; Endothelium; NO (nitric oxide); Renal artery

Indexed keywords

ARGININE DERIVATIVE; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; ENDOTHELIN 1; ENDOTHELIN RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; INDOMETACIN; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; N(G) NITROARGININE; NIMESULIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG INHIBITION; DRUG MECHANISM; MALE; MUSCLE CONTRACTILITY; NONHUMAN; PRIORITY JOURNAL; RABBIT; RENAL ARTERY; VASOCONSTRICTION;

ALLOXAN; ANIMALS; ANTIHYPERTENSIVE AGENTS; CYCLOOXYGENASE INHIBITORS; DIABETES MELLITUS, EXPERIMENTAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; INDOMETHACIN; MALE; NITRIC OXIDE SYNTHASE; NITROARGININE; PEPTIDES, CYCLIC; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RABBITS; RECEPTOR, ENDOTHELIN A; RENAL ARTERY; VASOCONSTRICTION;

EID: 33644903467     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.01.043     Document Type: Article

References (43)

1. 2 mimetic U46619 interaction, in type-2 hypertensive diabetic Zucker rats Diabetes Res. Clin. Pract. 63 2004 155 169
2. J.A. Alabadí, F.J. Miranda, S. Lloréns, R.F. Ruiz de Apodaca, J.M. Centeno, and E. Alborch Diabetes potentiates acetylcholine-induced relaxation in rabbit renal arteries Eur. J. Pharmacol. 415 2001 225 232
3. J.A. Alabadí, F.J. Miranda, S. Lloréns, J.M. Centeno, V.G. Marrachelli, and E. Alborch Mechanisms underlying diabetes enhancement of endothelin-1-induced contraction in rabbit basilar artery Eur. J. Pharmacol. 486 2004 289 296
4. V. Campean, F. Theiling, A. Paliege, M. Breyer, and S. Bachmann Key enzymes for renal prostaglandin synthesis: site-specific expression in rodent kidney (rat, mouse) Am. J. Physiol., Renal Physiol. 285 2003 F19 F32
5. C. Cardillo, C.M. Kilcoyne, R.O. Cannon, Iii, and J.A. Panza Interactions between nitric oxide and endothelin in the regulation of vascular tone of human resistance vessels in vivo Hypertension 35 2000 1237 1241
6. C. Cardillo, U. Campia, M.B. Bryant, and J.A. Panza Increased activity of endogenous endothelin in patients with type II diabetes mellitus Circulation 106 2002 1783 1787
7. U. Chakravarthy, A. McGinty, J. McKillop, P. Anderson, D.B. Archer, and E.R. Trimble Altered endothelin-1 induced contraction and second messenger generation in bovine retinal microvascular pericytes cultured in high glucose medium Diabetologia 37 1994 36 42
8. A.S. De Vriese, T.J. Verbeuren, J. Van De Voorde, N.H. Lameire, and P.M. Vanhoutte Endothelial dysfunction in diabetes Br. J. Pharmacol. 130 2000 963 974
9. P. D'Orleans-Juste, J. Labonte, G. Bkaily, S. Choufani, M. Plante, and J.C. Honore Function of the endothelin B receptor in cardiovascular physiology and pathophysiology Pharmacol. Ther. 95 2002 221 238
10. R.G. Evans, A.C. Madden, and E. Cotterill ET-receptor subtypes: roles in regional renal vascular actions of exogenous and endogenous endothelins in anesthetized rabbits J. Cardiovasc. Pharmacol. 35 2000 677 685
11. R. Haberberger, M. Schemann, H. Sann, and W. Kummer Innervation pattern of guinea pig pulmonary vasculature depends on vascular diameter J. Appl. Physiol. 82 1997 426 434
12. A. Habib, C. Creminon, Y. Frobert, J. Grassi, P. Pradelles, and J. Maclouf Demonstration of an inducible cyclooxygenase in human endothelial cells using antibodies raised against the carboxyl-terminal region of the cyclooxygenase-2 J. Biol. Chem. 268 1993 23448 23454
13. H. Haller Endothelial function. General considerations Drugs 53 1997 1 10
14. W.C. Hodgson, and R.G. King Effects of glucose, insulin or aldose reductase inhibition on responses to endothelin-1 of aortic rings from streptozotocin-induced diabetic rats Br. J. Pharmacol. 106 1992 644 649
15. R.L. Hopfner, and V. Gopalakrishnan Endothelin: emerging role in diabetic vascular complications Diabetologia 42 1999 1383 1394
16. J.P. Huidobro-Toro, and M.V. Donoso Sympathetic co-transmission: the coordinated action of ATP and noradrenaline and their modulation by neuropeptide Y in human vascular neuroeffector junctions Eur. J. Pharmacol. 500 2005 27 35
17. J.D. Imig, B.T. Pham, E.A. LeBlanc, K.M. Reddy, J.R. Falck, and E.W. Inscho Cytochrome P450 and cyclooxygenase metabolites contribute to the endothelin-1 afferent arteriolar vasoconstrictor and calcium responses Hypertension 35 2000 307 312
18. L. Jurzik, M. Froh, R.H. Straub, J. Scholmerich, and R. Wiest Up-regulation of nNOS and associated increase in nitrergic vasodilation in superior mesenteric arteries in pre-hepatic portal hypertension J. Hepatol. 43 2005 258 265
19. A receptors Am. J. Physiol., Renal Physiol. 286 2004 F660 F668
20. H.C. Lam, J.K. Lee, H.T. Chiang, S.J. Koh, T.M. Han, C.C. Lu, C.Y. Yang, and L.J. Hao Does endothelin play a role in the pathogenesis of early diabetic nephropathy? J. Cardiovasc. Pharmacol. 26 Suppl.3 1995 S479 S481
21. M. Lomnicka, K. Karouni, M. Sue, L.A. Wessel, and R.J. Bing Effects of nonsteroidal anti-inflammatory drugs on prostacyclin and thromboxane in the kidney Pharmacology 68 2003 147 153
22. B receptors and endothelial modulators in diabetes-induced hyperreactivity of the rabbit carotid artery to endothelin-1 Eur. J. Pharmacol. 486 2004 43 51
23. 2 of vasoconstriction induced by an alpha-agonist in mesenteric arterial bed from diabetic rats Diabetologia 41 1998 1410 1418
24. W.G. Mayhan Constrictor responses of the rat basilar artery during diabetes mellitus Brain Res. 783 1998 326 331
25. D.F. McAuley, A.G. Nugent, C. McGurk, S. Maguire, J.R. Hayes, and G.D. Johnston Vasoconstriction to endogenous endothelin-1 is impaired in patients with type II diabetes mellitus Clin. Sci. (Lond.) 99 2000 175 179
26. C.A. McIntyre, P.W. Hadoke, B.C. Williams, R.M. Lindsay, A.I. Elliott, and J.A. McKnight Selective enhancement of sensitivity to endothelin-1 despite normal endothelium-dependent relaxation in subcutaneous resistance arteries isolated from patients with Type I diabetes Clin. Sci. (Lond.) 100 2001 311 318
27. F.J. Miranda, J.A. Alabadí, S. Llorens, R.F. Ruiz De Apodaca, J.M. Centeno, and E. Alborch Influence of experimental diabetes on regulatory mechanisms of vascular response of rabbit carotid artery to acetylcholine Life Sci. 66 2000 2071 2080
28. F.J. Miranda, J.A. Alabadí, S. Lloréns, R.F. Ruiz De Apodaca, J.M. Centeno, and E. Alborch Diabetes-induced changes in endothelial mechanisms implicated in rabbit carotid arterial response to 5-hydroxytryptamine Eur. J. Pharmacol. 401 2000 397 402
29. F.J. Miranda, J.A. Alabadí, S. Lloréns, R.F. Ruiz De Apodaca, J.M. Centeno, and E. Alborch Experimental diabetes induces hyperreactivity of rabbit renal artery to 5-hydroxytryptamine Eur. J. Pharmacol. 439 2002 121 127
30. M. Miyataka, K.A. Rich, M. Ingram, T. Yamamoto, and R.J. Bing Nitric oxide, anti-inflammatory drugs on renal prostaglandins and cyclooxygenase-2 Hypertension 39 2002 785 789
31. N.J. Morrish, S.L. Wang, L.K. Stevens, J.H. Fuller, and H. Keen Mortality and causes of death in the WHO multinational study of vascular disease in diabetes Diabetologia 44 Suppl 2 2001 S14 S21
32. H.C. Nora, A.M. Cardozo, P. D'Orleans-Juste, and G.A. Rae Influences of indomethacin on contractions induced by endothelins in guinea pig isolated gallbladder J. Cardiovasc. Pharmacol. 36 Suppl. 1 2000 S267 S269
33. A.G. Nugent, C. McGurk, J.R. Hayes, and G.D. Johnston Impaired vasoconstriction to endothelin 1 in patients with NIDDM Diabetes 45 1996 105 107
34. M. Okumura, M. Imanishi, T. Yamashita, Y. Yamamura, S. Kim, H. Iwao, S. Tanaka, and S. Fujii Renal production of thromboxane and prostaglandins in a rat model of type 2 diabetes Life Sci. 66 2000 371 377
35. A.O. Oyekan, and J.C. McGiff Cytochrome P-450-derived eicosanoids participate in the renal functional effects of ET-1 in the anesthetized rat Am. J. Physiol. 274 1998 R52 R61
36. J. Quilley, and Y.J. Chen Role of COX-2 in the enhanced vasoconstrictor effect of arachidonic acid in the diabetic rat kidney Hypertension 42 2003 837 843
37. J.A. Rimarachin, J.A. Jacobson, P. Szabo, J. Maclouf, C. Creminon, and B.B. Weksler Regulation of cyclooxygenase-2 expression in aortic smooth muscle cells Arterioscler. Thromb. 14 1994 1021 1031
38. E. Sanz, N. Fernández, L. Monge, M.A. Martínez, B. Climent, G. Diéguez, and A.L. García-Villalón Effects of diabetes on the vascular response to nitric oxide and constrictor prostanoids: gender and regional differences Life Sci. 72 2003 1537 1547
39. L.H. Smith, O. Boutaud, M. Breyer, J.D. Morrow, J.A. Oates, and D.E. Vaughan Cyclooxygenase-2-dependent prostacyclin formation is regulated by low density lipoprotein cholesterol in vitro Arterioscler. Thromb. Vasc. Biol. 22 2002 983 988
40. A. Sorokin, and D.E. Kohan Physiology and pathology of endothelin-1 in renal mesangium Am. J. Physiol., Renal Physiol. 285 2003 F579 F589
41. 2 EP4 receptors J. Am. Soc. Nephrol. 15 2004 1189 1198
42. A receptor via influx of calcium and is independent of protein kinase C Hypertension 26 1995 1035 1040
43. M. Yanagisawa, H. Kurihara, S. Kimura, Y. Tomobe, M. Kobayashi, Y. Mitsui, Y. Yazaki, K. Goto, and T. Masaki A novel potent vasoconstrictor peptide produced by vascular endothelial cells Nature 332 1998 411 415